Research

CONSTRUCT

Trial of the Month

This is a pragmatic trial to compare the clinical- and cost-effectiveness of infliximab and ciclosporin in the treatment of acute severe ulcerative colitis that fails to respond to intravenous steroids.

Update: March 2011

Thirty-six sites have now been visited and trained.  Out of these sites 33 have been fully activated.  183 patients have been recruited to a cohort of patients admitted with acute severe colitis, and 29 of these have been recruited to the trial following failure to respond to steroids.

Training visits have been arranged for a further four sites have R&D approval.  It is anticipated that they will be activated between mid February – mid March 2011.  There are also 17 sites seeking R&D approval and a further 17 new sites are considering taking part.

With the number of active sites increasing we hope to see recruitment figures grow, but we are concerned by the slow rate of recruitment in activated sites to date.  This is much lower than had been predicted.

We have recently issued all activated sites with a recruitment guide to ensure that all possible cases are being picked up including ways to identify patients.  The guide also reiterates that CONSTRUCT is a pragmatic study with the ability for sites to follow their normal practice (including the flexibility to use clinical judgement and clinical decisions, to use clinical criteria to determine patients’ eligibility and to adapt treatment to patient).

If you would like details please contact us on This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Predicting 5-Aminosalicylate Nephrotoxicity in Patients with IBD (New Trial)

This is the first of a series of genetic studies, lead by the UK IBD Genetics consortium, investigating rare side effects to drugs used in patients with IBD. Our aim is to recruit 200 UK patients over the next 2 years. We anticipate that each hospital might be looking after 2-3 patients who meet the inclusion criteria.  Participation involves a blood test for DNA extraction, and completion of a case report form, patient questionnaire and consent form.

Nephrotoxicity is defined by a series of major and minor criteria which allow us to rank how certain we are that the 5-ASA is responsible. Any patient that meets the major criteria might be eligible: Current age > 18 years; normal Creatinine or eGFR at baseline; ≥50% rise in serum creatinine (with corresponding fall in eGFR, anytime after introduction of 5-ASA; expert renal opinion implicates 5-ASA

If would like to get involved, either as a research site or patient identification (PIC) site then please contact:

Tracey Hill
Trial Co-ordinator
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: 07900 161244

Tariq Ahmad
Chief Investigator
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Idiosyncratic Drug-induced Liver Injury Study (DILIGEN)

The international Drug-induced Liver Injury Consortium (iDILIC), is studying the genetic susceptibility to idiosyncratic drug-induced liver injury. The UK arm of the study is DILIGEN. The study, involves collecting DNA from cases and suitable controls for a genome wide association study (GWAS) with the aim of identifying polymorphisms predictive of the development of drug-related liver injury and hence allowing the possibility of prevention. We will be grateful to physicians treating idiosyncratic drug-induced liver injury cases, particularly BSG members, to put us in contact with suitable patients.

Patients who developed one of the following due to drug-induced liver injury are suitable to be included:

HANDEL

Histological AssessmeNt Determining EpitheliaL Response.

Chief investigator: Professor Janusz Jankowski
Sponsor: Queen Mary, University of London

Design: Observational/Interventional study collecting blood and tissue samples from patients recruited into Cancer Oesophagus Gefitinib-COG Study and blood samples from patient's family members with history of severe oesophagitis, Barrett's oesophagus and/or oesophageal cancer for genetic and molecular biological studies.

Planned /actual start date: 15/01/2010
Planned close date: 21/03/2014

Target number of patients: 1000
Number of patients recruited: Recruiting

Number of centres needed: 35
Number of centres recruiting: 1

Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it (Manoj Nanji, Trial manager)
This e-mail address is being protected from spambots. You need JavaScript enabled to view it (Prof Janusz Jankowski, Chief Investigator)

STOPAH

STOPAH (Steroids or Pentoxifylline in Alcoholic Hepatitis) is a multicentre UK trial funded by NIHR-HTA. This is a vital study in UK hepatology looking to prove the role of steroids or pentoxifylline versus placebo in the treatment of a condition which is increasingly common in the UK. Patients with DF>32 are eligible and the study is designed to be pragmatic with few exclusions to treatment. Primary outcome is 30 day mortality but with follow-up to a year.

Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it (chief investigator)
This e-mail address is being protected from spambots. You need JavaScript enabled to view it (clinical trial coordinator)

Update: March 2011

This has been delayed partly due to issues regarding trial drug provision. A hub-and-spoke distribution provides the most cost-efficient method of provision, but has caused some logistical difficulties at a local level. However, these are starting to be resolved and the first patients are now being recruited. Please contact the CI or trial coordinator if you are interested in taking part. .

 

Page 4 of 6